V enous thromboembolism (VTE) remains a major challenge in the care of critically ill patients. Patients in the intensive care unit (ICU) are at high risk for both deep vein thrombosis (DVT) and pulmonary embolism (PE).
PE frequently occurs in the critically ill patient within days of admission and is an important cause of in-hospital mortality. The common occurrence of PE has been shown at post mortem in these patients. It is therefore a cardiovascular emergency. Traditional treatment is with heparin therapy, but intravenous thrombolysis may be necessary in severe cases, especially when associated with obstructive shock. Developing technologies now allow for non-pharmacological techniques to be used where thrombolysis has been ineffective or is inappropriate: this can be catheter fragmentation, surgical embolectomy and extracorporeal circulatory support, which may be used as a bridge to further treatment in very unstable patients.
Prevention of PE is the key. Low doses of heparin are the usual prophylactic measure, but are sometimes contraindicated. In this case inferior vena cava (IVC) filters can be inserted to prevent the migration of thromboemboli from the lower parts of the body to the lungs, but their use is quite complicated. A recent Medical Device Alert from the Medicines and Healthcare Regulatory Agency (MHRA) suggests that there is a problem removing these IVC filters; in addition the placement of such filters has traditionally been the preserve of interventional radiologists and in many hospitals such expertise may not always be available, or may be too far from the ICU for a patient in a critical condition. It may be that the emergence of the Angel ® Catheter (BiO 2 Medical) provides an important piece of this jigsaw puzzle, enabling easy and straightforward protection against PE during a critical window of risk.
In this educational supplement for the Journal of the Intensive Care Society, sponsored by BiO 2 Medical, we are delighted to welcome some superb authors who will discuss why and how we need to implement strategies to prevent PE.
To set the scene we welcome Beverley Hunt, who is Professor of Haemostasis and Thrombosis and Professor of the Haemostasis Research Unit at Guy' s and St Thomas' Hospital in London and Medical Director of Lifeblood, the thrombosis charity. She reminds us that a systematic review in the USA, ranked PE as the most common preventable cause of hospital death, and thromboprophylaxis as the main strategy to improve patient safety.
Matthew Gibson, an Interventional Radiologist at the Royal Berkshire Hospital in Reading, UK, summarises the role of IVC filters. Dr Angel, a Pulmonologist and Intensive Care Physician, then gives us an insight into the development of a new breed of IVC device, which may well have a major impact on future thromboprophylactic strategies. The device can be easily placed at the patient' s bedside without the need for fluoroscopic imaging, and is relatively easy to remove when the patient no longer needs prophylaxis or when pharmacological prophylaxis can be recommenced.
We present two case histories from Belgium and three from the UK evaluating the early use of the Angel Catheter.
We conclude with an article from Christian Rylander' s unit in Gothenberg, Sweden, looking at the incidence and treatment options for massive PE, including the use of extracorporeal membrane oxygenation. A recently devised algorithm for management of PE is included. 
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